WitrynaInfo. I am an immunologist with experience in cell and immunological assays, cell culture, patch-clamp technique, Flow cytometry, working with clinical samples various model systems including mice, rats, data analysis, and scientific writer. I have 20+ peer-reviewed publications including Molecular and Cell Biology 'spotlight of the issue' and ... WitrynaExpert Researcher in antitumor Immune Response, Immuno-Oncology and Cancer Immunotherapy. Extensive experience working in Pre-Clinical / Translational Research projects. 14+ years of Scientist Research including studies in Tumor microenvironment (Tregs, MDSC, TILs, neoantigens, etc.), Immuno Checkpoint Blockers, Adoptive …
National Center for Biotechnology Information
WitrynaHighly motivated, versatile and result-oriented Scientist/Consultant/Subject Matter Expert with strong research background and exceptional publication record in cell and molecular biology, virology, oncology, immunology, immunotherapy, cell and gene therapy especially CAR-T cell therapy. Expertise in several in vitro, in vivo and ex vivo models … Witryna11 kwi 2024 · Numerous studies have investigated the various cellular responses against genotoxic stress, including those mediated by focal adhesions. We here identified a novel type of focal adhesion remodelling that occurs under genotoxic stress conditions, which involves the replacement of active focal adhesion kinase (FAK) with FAK … sims 4 gothic maxis match
Antibody-dependent cell-mediated (k cell) cytotoxicity against …
Witryna30 cze 2024 · However, due to their mode of action, these treatments are associated with several immune-related adverse events (irAEs), including immune-mediated … Witryna1 dzień temu · The advent of immunotherapy has made an indelible mark on the field of cancer therapy, especially the application of immune checkpoint inhibitors in clinical practice. Although immunotherapy has proven its efficacy and safety in some tumors, many patients still have innate or acquired resistance to immunotherapy. The … Witryna11 kwi 2024 · Immune-mediated pneumonitis occurred in 3% to 7% of early trials, Davies said, and median onset is 60 to 90 days from the start of immune checkpoint inhibitor (ICI) therapy. Mortality rates are ... rbt south cave